Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — Q1 2025 Earnings Presentation
21 slides from Hls Therapeutics's earnings presentation, May 8, 2025
Slide 1: Q1 2025 Conference Call
Q1 2025 Conference Call May 8, 2025 Craig Millian, CEO John Hanna, CFO Brian Walsh, CCO TSX - HLS
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Q1 2025: Financial Highlights
Q1 2025: Financial Highlights HLS Canadian Revenue: product sales* 13% Operating $12.6M expenses^ 20% Vascepa net sales* 34% Cash from operations: Adjusted $3.5M EBITDA 41% Clozaril Canada net sales* 1% Adjusted EBITDA: Adjusted $3.8M EBITDA 78% Clozaril U.S. (excluding Royalties) net sales 3% *in l
Slide 4: 2025 Guidance Unchanged
2025 Guidance Unchanged Vascepa Revenue: Clozaril US Revenue: Adjusted USD $12-12.3M EBITDA: CAD $26.5-28.5M (2-4% decline) (18-26% growth) $19.5-20.5M 6-11% (17-23% growth) Growth Clozaril Canada Revenue: Royalty Revenue: CAD $35.5-36M USD $0.6-0.75M (flat) (50-60% decline) Toronto Stock Exchange (
Slide 5: Expanding Cardiovascular Portfolio: NEXLETOL & NEXLIZET
Expanding Cardiovascular Portfolio: NEXLETOL & NEXLIZET Overview Value Proposition Timeline Oral CV medicines Differentiated Mechanism of Action Q4 24: New Drug Submissions filed FDA approved 2020 (lower LDL-C) Strong CV outcomes data Q4 25: Health Canada approval expected Label expanded 2024 (reduc
Slide 6: A New Paradigm in the Treatment of Cardiovascular Risk
A New Paradigm in the Treatment of Cardiovascular Risk Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 7: Key Actions Taken to Ensure Profitable Growth
Key Actions Taken to Ensure Profitable Growth Bringing Primary Care Stabilizing the Payer Mix Sales In-house ~$4M annual savings from Enhanced physician targeting based on payer dynamics exiting promotional services agreement Field Sales Leadership Improved retention via co-pay program restructuring
Slide 8: Maintaining Solid Prescribing Growth
Maintaining Solid Prescribing Growth Weekly TRx Units Since Launch 3,500 3,000 29% increase 2,500 in unit demand* 2,000 1,500 34% increase 1,000 in revenue (in C$)* 500 *Q1 2025 compared to Q1 2024 0 Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, c
Slide 9: NEXLETOL & NEXLIZET - Product Overview
NEXLETOL & NEXLIZET - Product Overview NEXLETOL: Bempedoic acid monotherapy Daily oral non-statin treatment Liver-activated, avoids muscle symptoms LDL-C reduction: 17-18% NEXLIZET: Combination therapy Bempedoic acid + ezetimibe Single daily pill convenience LDL-C reduction: ~38% Toronto Stock Excha
Slide 10: Next Step in Cardiovascular Risk Reduction
Next Step in Cardiovascular Risk Reduction * - As pre-specified exploratory analysis © 2025 Esperion Therapeutics, Inc. All rights reserved. Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary
Slide 11: Canadian Market Opportunity
Canadian Market Opportunity ~200K >300K >500K Patients not at target LDL-C Canadians unable to take Canadian levels despite statin/ezetimibe recommended statin therapy patients therapy Source: IQVIA data and primary market research estimates 600-700K patients on statin/ezetimibe therapy of which 30-
Slide 12: Strategic Integration
Strategic Integration Leverages existing High overlap Minimal incremental Vascepa of target OpEx and no infrastructure prescribers additional headcount required Q4 2025 1H 2026 Health Canada Private insurance approval expected coverage Early 2026 2027-2028 Commercial launch Full public coverage Toro
Slide 13: Three products, one goal: reducing cardiovascular risk for more Canadians
Three products, one goal: reducing cardiovascular risk for more Canadians Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update HLS THERAPEUTICS INC.
Slide 14: Life-changing medicine for Treatment Resistant Schizophrenia
Life-changing medicine for Treatment Resistant Schizophrenia Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 15: Continued Execution on Regional Strategies
Continued Execution on Regional Strategies Western Canada market share growth through CSAN differentiation Ontario improve Clozaril utilization amongst TRS patients Quebec leverage CSAN support for patient retention U.S. leverage specialty pharma partnership *Nova Scotia strategy similar to Ontario
Slide 16: Financial Review: Strengthening Foundation to Support Growth
Financial Review: Strengthening Foundation to Support Growth Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 17: Revenue Growth from Marketed Products
Revenue Growth from Marketed Products Total Revenue ($000’s) Marketed Product Revenue ($000’s) 14,000 14,000 12,000 12,000 13% growth* Canadian product sales 10,000 10,000 of Vascepa and Clozaril 8,000 8,000 6,000 1% 5% 6,000 4,000 4,000 3% growth 2,000 2,000 US sales of Clozaril 0 0 Q1 2024 Q1 2025
Slide 18: Reducing Expenses and Improving Margins
Reducing Expenses and Improving Margins Operating Expenses - excluding Cost of Sales Adjusted EBITDA - excluding Royalties ($000’s) ($000’s) 5,000 4,000 4,500 3,500 4,000 3,000 3,500 2,500 3,000 20% 78% 2,500 2,000 2,000 1,500 1,500 1,000 1,000 500 500 0 0 Q1 2024 Q1 2025 Q1 2024 Q1 2025 Toronto Sto
Slide 19: Strengthening Balance Sheet
Strengthening Balance Sheet Summary Balance Sheet & Capitalization De-levering the Balance Sheet (US$ millions) At Dec 31, 2024 At Mar 31, 2025 Made $3M principal debt payment in Q1 2025 Cash and Cash Equivalents 17.5 17.7 1 Senior Secured Term Loan and Revolver 67.4 64.5 Net Debt (Term Loan less Ca
Slide 20: Q1 Summary
Q1 Summary 1 Grew promoted product portfolio 2 Reduced operating expenses 3 De-levered the balance sheet and increased financial flexibility 4 Launched share buyback 5 Subsequent to Q1, in-licensed NEXLETOL & NEXLIZET for cardiovascular market Building a foundation for long-term value creation throu
Slide 21: Q1 2025 Conference Call
Q1 2025 Conference Call May 8, 2025 Craig Millian, CEO John Hanna, CFO Brian Walsh, CCO TSX - HLS